Mandate

Vinge advises Hansa Medical in connection with directed share issue

October 24, 2016

The board of directors of Hansa Medical proposes a capital raising through a directed share issue, whereby the company will receive approximately SEK 185 million.

The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.

Related

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025

Vinge advises The Qt Company Ltd on its public offer for I.A.R. Systems Group AB (publ)

The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share
July 04, 2025

Vinge has advised Consolid on the establishment of Consolid Equity III

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025